Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 10 de 10
1.
J Cosmet Dermatol ; 21(3): 1057-1064, 2022 Mar.
Article En | MEDLINE | ID: mdl-33955628

BACKGROUND: Considerable parts of the global population are affected by androgenetic alopecia (AGA). AIMS: The efficacy of a foam containing nicotinic acid hexyl ester, polyphenols, zinc, glycine, and caffeine in comparison with a vehicle control foam was assessed in a double-blind vehicle-controlled study in men with AGA over 6 months. PATIENTS/METHODS: Sixty-two men with AGA were assigned either to the active ingredients (verum) or the vehicle group. They applied the products twice daily on affected scalp areas over 6 months. Automated phototrichograms were obtained at baseline, after 3 and 6 months. In addition, a clinical rating by a dermatologist and by the subjects themselves was documented using standardized questionnaires. RESULTS: The reduction of the telogen rate from T0 to T6 was significantly stronger in the verum group compared to the vehicle group. The reduction was significant from T0 to T3 and T6 in the verum group, but in the vehicle group only from T0 to T3, not to T6. Significantly increased hair density was noticed in both groups at all time points, but the change from T0 to T6 did not differ significantly between the groups. Cosmetic acceptance of the foam and its application regimen was generally good in both groups. Slight reddening and burning after application of verum in six cases was probably due to the presence of hexyl nicotinate. CONCLUSION: The study demonstrated a reduction of the telogen rate by a cosmetic foam in men affected by AGA, indicating a benefit for cosmetic intervention against male pattern hair loss.


Alopecia , Hair , Alopecia/drug therapy , Double-Blind Method , Humans , Male , Prospective Studies , Treatment Outcome
2.
J Clin Oncol ; 37(32): 3000-3008, 2019 11 10.
Article En | MEDLINE | ID: mdl-31557067

PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation. Here, we report the final analysis with 72 months of median follow up. PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation. DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points. The analysis was by intention to treat. Disease and survival information were collected quarterly. RESULTS: From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN). Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm. In the final analysis, median follow up was 72 months (interquartile range, 67-77 months). No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87). The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively). Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported. CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis. These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis.


Melanoma/mortality , Melanoma/surgery , Skin Neoplasms/mortality , Skin Neoplasms/surgery , Aged , Disease-Free Survival , Germany/epidemiology , Humans , Lymph Node Excision/methods , Lymph Node Excision/statistics & numerical data , Melanoma/pathology , Middle Aged , Neoplasm Metastasis , Prospective Studies , Sentinel Lymph Node/pathology , Sentinel Lymph Node/surgery , Skin Neoplasms/pathology , Treatment Outcome , Melanoma, Cutaneous Malignant
3.
Lancet Oncol ; 17(6): 757-767, 2016 Jun.
Article En | MEDLINE | ID: mdl-27161539

BACKGROUND: Complete lymph node dissection is recommended in patients with positive sentinel lymph node biopsy results. To date, the effect of complete lymph node dissection on prognosis is controversial. In the DeCOG-SLT trial, we assessed whether complete lymph node dissection resulted in increased survival compared with observation. METHODS: In this multicentre, randomised, phase 3 trial, we enrolled patients with cutaneous melanoma of the torso, arms, or legs from 41 German skin cancer centres. Patients with positive sentinel lymph node biopsy results were eligible. Patients were randomly assigned (1:1) to undergo complete lymph node dissection or observation with permuted blocks of variable size and stratified by primary tumour thickness, ulceration of primary tumour, and intended adjuvant interferon therapy. Treatment assignment was not masked. The primary endpoint was distant metastasis-free survival and analysed by intention to treat. All patients in the intention-to-treat population of the complete lymph node dissection group were included in the safety analysis. This trial is registered with ClinicalTrials.gov, number NCT02434107. Follow-up is ongoing, but the trial no longer recruiting patients. FINDINGS: Between Jan 1, 2006, and Dec 1, 2014, 5547 patients were screened with sentinel lymph node biopsy and 1269 (23%) patients were positive for micrometastasis. Of these, 483 (39%) agreed to randomisation into the clinical trial; due to difficulties enrolling and a low event rate the trial closed early on Dec 1, 2014. 241 patients were randomly assigned to the observation group and 242 to the complete lymph node dissection group. Ten patients did not meet the inclusion criteria, so 233 patients were analysed in the observation group and 240 patients were analysed in the complete lymph node dissection group, as the intention-to-treat population. 311 (66%) patients (158 in the observation group and 153 in the dissection group) had sentinel lymph node metastases of 1 mm or less. Median follow-up was 35 months (IQR 20-54). Distant metastasis-free survival at 3 years was 77·0% (90% CI 71·9-82·1; 55 events) in the observation group and 74·9% (69·5-80·3; 54 events) in the complete lymph node dissection group. In the complete lymph node dissection group, grade 3 and 4 events occurred in 15 patients (6%) and 19 patients (8%) patients, respectively. Adverse events included lymph oedema (grade 3 in seven patients, grade 4 in 13 patients), lymph fistula (grade 3 in one patient, grade 4 in two patients), seroma (grade 3 in three patients, no grade 4), infection (grade 3 in three patients, no grade 4), and delayed wound healing (grade 3 in one patient, grade 4 in four patients); no serious adverse events were reported. INTERPRETATION: Although we did not achieve the required number of events, leading to the trial being underpowered, our results showed no difference in survival in patients treated with complete lymph node dissection compared with observation only. Consequently, complete lymph node dissection should not be recommended in patients with melanoma with lymph node micrometastases of at least a diameter of 1 mm or smaller. FUNDING: German Cancer Aid.


Lymph Node Excision/mortality , Melanoma/surgery , Neoplasm Recurrence, Local/surgery , Sentinel Lymph Node Biopsy/mortality , Sentinel Lymph Node/surgery , Adult , Aged , Case-Control Studies , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Melanoma/pathology , Middle Aged , Neoplasm Micrometastasis , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Sentinel Lymph Node/pathology , Survival Rate
5.
Contact Dermatitis ; 67(4): 234-7, 2012 Oct.
Article En | MEDLINE | ID: mdl-22624993

BACKGROUND: There is increasing evidence that reactive oxygen species play an important role in the development of both irritant and allergic contact dermatitis. OBJECTIVES: To assess the potential of topical antioxidants to prevent the development of experimentally induced irritant contact dermatitis. METHODS: We evaluated the effect of a cream containing a combination of antioxidants on sodium lauryl sulfate-induced irritant contact dermatitis in the repetitive washing test. As readout parameters for skin barrier function and cutaneous inflammation stratum corneum hydration, cutaneous blood flow and transepidermal water loss were assessed in 25 volunteers with bioengineering methods. RESULTS: In comparison with the cream base and a frequently used barrier cream, the antioxidant cream had high radical scavenging activity and effectively protected the skin from chemical-induced irritation. CONCLUSIONS: The superiority of the cream with antioxidants to the cream base suggests that reactive oxygen species, at least in part, play a role in the development of irritant contact dermatitis.


Antioxidants/therapeutic use , Dermatitis, Irritant/etiology , Dermatitis, Irritant/prevention & control , Hand Dermatoses/etiology , Hand Dermatoses/prevention & control , Skin Cream/therapeutic use , Dermatitis, Irritant/physiopathology , Double-Blind Method , Hand Dermatoses/physiopathology , Humans , Phytotherapy , Plant Extracts/therapeutic use , Reactive Oxygen Species , Resedaceae , Sodium Dodecyl Sulfate/pharmacology , Tocopherols/therapeutic use , Ubiquinone/therapeutic use
10.
Skin Res Technol ; 10(1): 1-9, 2004 Feb.
Article En | MEDLINE | ID: mdl-14731242

UNLABELLED: BACKGROUND AND PROBLEM: It is well known that the damaging effect of surfactants on the stratum corneum varies according to the surfactant used. The present investigations aim to compare four standard commercial cleansing solutions (Esemptan Cleansing Lotion, Stephalen Shower Gel, Manipur Antimicrobial Cleansing Solution and Tork Mevon 55 Liquid Soap) with respect to their cleansing and skin barrier-damaging effects. MATERIAL AND METHODS: The cleansing effect of the solutions was determined in relation to their concentrations in a first experimental series involving 15 subjects using a standardised test method. The product concentrations with the most divergent cleansing effects were tested for their dehydrating (corneometry), epidermal barrier-damaging (TEWL) and irritating effects (laser Doppler) in a standardised washing test. In a second experimental series, the concentration used for the cleansing solutions was based on the quantity of cleansing solution obtained from dispenser actuations (six actuations/L). These concentrations were used to test the cleansing and damaging effect on the stratum corneum using the same methods as in the first experimental series. RESULTS: There were no significant differences in the first experimental series. In the second experimental series, Stephalen Shower Gel showed disadvantages in terms of a small cleansing effect, but without evidence of a smaller stratum corneum-damaging effect, and Tork Mevon 55 Liquid Soap showed advantages in terms of a smaller stratum corneum-damaging effect, but without evidence of a smaller cleansing effect. CONCLUSIONS: These studies showed that the relationship between the cleansing and the damaging effect on the stratum corneum can be properly assessed only by testing different concentrations. Furthermore, this experimental approach allowed to differentiate the four tested cleansing solutions.


Detergents/adverse effects , Skin Diseases/chemically induced , Skin/drug effects , Surface-Active Agents/adverse effects , Adult , Dehydration/chemically induced , Emulsifying Agents/adverse effects , Female , Humans , Irritants/adverse effects , Laser-Doppler Flowmetry , Male , Skin/blood supply
...